Printer Friendly

Mylan Obtains Three Patents Protecting Perforomist Inhalation Solution.

Mylan, Inc. (Pittsburgh, PA) announced that its subsidiary Dey L.P. has been issued several additional United States patents protecting the company's Perforomist Inhalation Solution, a chronic obstructive pulmonary disease (COPD) treatment.

United States Patent 7,462,645 was issued Dec. 9, 2008, and is directed to treatment through the administration of a ready-to-use, storage stable composition of formoterol. This patent covers Dey's Perforomist Solution, and its term extends until June 22, 2021. The patent will be listed in the "Orange Book," giving Dey four Orange Book-listed patents covering Perforomist Solution.

United States Patents 7,465,756 and 7,473,710 were issued December 16, 2008, and January 6, 2009, respectively. These patents are directed to compositions of "R-formoterol," a specific form of the formoterol molecule, and their use.

In addition, Dey has received a "Notice of Allowance" on yet another patent also directed to the use of R-formoterol. This patent is expected to issue shortly. Upon its issuance, Dey will possess seven patents directed to compositions of formoterol, R-formoterol and/or their uses.

Mylan's Vice Chairman and CEO Robert J. Coury stated: "We are very pleased with the recent issuance of these additional patents, which we believe only further bolster Dey's already strong intellectual property portfolio, and we will continue to aggressively protect and assert Dey's IP rights. Dey is currently pursuing a patent infringement lawsuit against Sepracor relating to its Brovana product."

Dey also has additional pending United States patent applications directed to formoterol-containing compositions and their use in the treatment of respiratory conditions.

Mylan, which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.

Dey L.P., a subsidiary of Mylan, is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the United States leader in sales of nebulized respiratory medication, Dey L.P. puts patients first through its development of innovative and affordable therapies.

Mylan, Inc.

+1-724-514-1968

www.mylan.com
COPYRIGHT 2008 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Dec 1, 2008
Words:391
Previous Article:Idenix Pharmaceuticals Initiates Study for Treatment of Hepatitis C Virus.
Next Article:Bavarian Nordic's Encouraged to File Complaint Against Oxford BioMedica.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters